US3758475A
(en)
|
1971-07-20 |
1973-09-11 |
Sandoz Ag |
Pyrido(2,3-d)pyrimidin 2 ones
|
IT1226048B
(it)
|
1981-12-14 |
1990-12-10 |
Medea Res Srl |
Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative
|
EP0081756B1
(en)
|
1981-12-14 |
1985-05-15 |
MEDEA RESEARCH S.r.l. |
New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
|
US4501729A
(en)
|
1982-12-13 |
1985-02-26 |
Research Corporation |
Aerosolized amiloride treatment of retained pulmonary secretions
|
US5981714A
(en)
|
1990-03-05 |
1999-11-09 |
Genzyme Corporation |
Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
|
JP3167762B2
(ja)
|
1990-11-27 |
2001-05-21 |
武田薬品工業株式会社 |
ピリドピリダジン誘導体およびその用途
|
US5612360A
(en)
|
1992-06-03 |
1997-03-18 |
Eli Lilly And Company |
Angiotensin II antagonists
|
CA2107196A1
(en)
|
1992-09-29 |
1994-03-30 |
Mitsubishi Chemical Corporation |
Carboxamide derivatives
|
GB9317764D0
(en)
|
1993-08-26 |
1993-10-13 |
Pfizer Ltd |
Therapeutic compound
|
ES2129679T3
(es)
|
1993-10-21 |
1999-06-16 |
Searle & Co |
Derivados que contienen el grupo amidino, utiles como inhibidores de la sintasa de oxido nitrico.
|
DE4405712A1
(de)
|
1994-02-23 |
1995-08-24 |
Basf Ag |
Substituierte Naphthyridine und deren Verwendung
|
IL113313A
(en)
|
1994-04-11 |
1999-09-22 |
Sankyo Co |
Heterocyclic compounds and pharmaceutical compositions containing the same
|
CZ289031B6
(cs)
|
1994-09-27 |
2001-10-17 |
Janssen Pharmaceutica N. V. |
Deriváty N-substituovaných piperidinylových bicyklických benzoátů
|
US5656256A
(en)
|
1994-12-14 |
1997-08-12 |
The University Of North Carolina At Chapel Hill |
Methods of treating lung disease by an aerosol containing benzamil or phenamil
|
US5510379A
(en)
|
1994-12-19 |
1996-04-23 |
Warner-Lambert Company |
Sulfonate ACAT inhibitors
|
US5585115A
(en)
|
1995-01-09 |
1996-12-17 |
Edward H. Mendell Co., Inc. |
Pharmaceutical excipient having improved compressability
|
WO1997036876A1
(en)
|
1996-04-03 |
1997-10-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6849733B1
(en)
|
1996-08-23 |
2005-02-01 |
Agouron Pharmaceuticals, Inc. |
Neuropeptide-Y ligands
|
JP2002511054A
(ja)
|
1996-12-30 |
2002-04-09 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシル蛋白トランスフェラーゼ阻害薬
|
CO4920215A1
(es)
|
1997-02-14 |
2000-05-29 |
Novartis Ag |
Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
|
US5948814A
(en)
|
1997-02-20 |
1999-09-07 |
The Curators Of The University Of Missouri |
Genistein for the treatment of cystic fibrosis
|
WO1998047868A1
(en)
|
1997-04-18 |
1998-10-29 |
Smithkline Beecham Plc |
Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
|
TR200000896T2
(tr)
|
1997-10-02 |
2000-09-21 |
Sankyo Company Limited |
Amidokarboksilik asit türevleri.
|
EP1054996B1
(en)
|
1998-02-17 |
2004-01-28 |
G.D. SEARLE & CO. |
Process for the enzymatic resolution of lactams
|
ES2188264T3
(es)
|
1998-06-08 |
2003-06-16 |
Schering Corp |
Antagonistas del receptor del neuropeptido y5.
|
US6426331B1
(en)
|
1998-07-08 |
2002-07-30 |
Tularik Inc. |
Inhibitors of STAT function
|
AUPP609198A0
(en)
|
1998-09-22 |
1998-10-15 |
Curtin University Of Technology |
Use of non-peptidyl compounds for the treatment of insulin related ailments
|
CA2347770A1
(en)
|
1998-12-18 |
2000-06-22 |
Bristol-Myers Squibb Pharma Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
DK1035115T3
(da)
|
1999-02-24 |
2005-01-24 |
Hoffmann La Roche |
4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
|
RU2238264C2
(ru)
|
1999-02-24 |
2004-10-20 |
Ф.Хоффманн-Ля Рош Аг |
Производные бензола или пиридина и фармацевтическая композиция на их основе
|
KR100437587B1
(ko)
|
1999-02-24 |
2004-06-30 |
에프. 호프만-라 로슈 아게 |
3-페닐피리딘 유도체 및 그의 뉴로키닌-1 수용체길항제로서의 용도
|
GB2347739A
(en)
*
|
1999-03-09 |
2000-09-13 |
Pfizer Ltd |
Powder Analysis
|
UA71971C2
(en)
|
1999-06-04 |
2005-01-17 |
Agoron Pharmaceuticals Inc |
Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
|
WO2000078733A1
(de)
|
1999-06-18 |
2000-12-28 |
Bayer Aktiengesellschaft |
Phenoxyfluorpyrimidine
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
WO2001046165A2
(en)
|
1999-12-16 |
2001-06-28 |
Novartis Ag |
N-heteroaryl-amides and their use as parasiticides
|
WO2001051919A2
(en)
|
2000-01-07 |
2001-07-19 |
Transform Pharmaceuticals, Inc. |
High-throughput formation, identification, and analysis of diverse solid-forms
|
WO2001054690A1
(en)
|
2000-01-28 |
2001-08-02 |
Biogen, Inc. |
Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
|
AU2001234689A1
(en)
|
2000-02-01 |
2001-08-14 |
Cor Therapeutics, Inc. |
Bivalent phenylene inhibitors of factor xa
|
US20010047100A1
(en)
|
2000-04-26 |
2001-11-29 |
Kjaersgaard Hans Joergen |
Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
|
WO2001083517A1
(en)
|
2000-05-03 |
2001-11-08 |
Tularik Inc. |
Stat4 and stat6 binding dipeptide derivatives
|
US6499984B1
(en)
|
2000-05-22 |
2002-12-31 |
Warner-Lambert Company |
Continuous production of pharmaceutical granulation
|
WO2001092235A1
(en)
|
2000-06-01 |
2001-12-06 |
Bristol-Myers Squibb Pharma Company |
LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
EP1317452B1
(en)
|
2000-09-15 |
2006-05-17 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
JP4272338B2
(ja)
|
2000-09-22 |
2009-06-03 |
バイエル アクチェンゲゼルシャフト |
ピリジン誘導体
|
WO2002028348A2
(en)
|
2000-10-04 |
2002-04-11 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treatment of cystic fibrosis
|
GB2367816A
(en)
|
2000-10-09 |
2002-04-17 |
Bayer Ag |
Urea- and thiourea-containing derivatives of beta-amino acids
|
DE60104014T2
(de)
|
2000-10-20 |
2005-08-11 |
Merck Patent Gmbh |
Chirale binaphtol-verbindungen
|
US6884782B2
(en)
|
2000-11-08 |
2005-04-26 |
Amgen Inc. |
STAT modulators
|
JP4323802B2
(ja)
|
2000-12-01 |
2009-09-02 |
エムジーアイ・ジーピー・インコーポレーテッド |
化合物およびその使用
|
GB0102687D0
(en)
|
2001-02-02 |
2001-03-21 |
Pharmacia & Upjohn Spa |
Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
US6531597B2
(en)
|
2001-02-13 |
2003-03-11 |
Hoffmann-La Roche Inc. |
Process for preparation of 2-phenyl acetic acid derivatives
|
WO2003084997A1
(en)
|
2001-04-10 |
2003-10-16 |
Transtech Pharma, Inc. |
Probes, systems and methods for drug discovery
|
BR0209151A
(pt)
|
2001-04-23 |
2004-07-13 |
Hoffmann La Roche |
Uso de antagonistas de receptor nk-1 contra hiperplasia prostática benigna
|
SK15432003A3
(sk)
|
2001-05-22 |
2004-05-04 |
Neurogen Corporation |
5-Substituované 2-arylpyridíny
|
US20030083345A1
(en)
|
2001-07-10 |
2003-05-01 |
Torsten Hoffmann |
Method of treatment and/or prevention of brain, spinal or nerve injury
|
US6627646B2
(en)
|
2001-07-17 |
2003-09-30 |
Sepracor Inc. |
Norastemizole polymorphs
|
US20030144350A1
(en)
|
2001-07-20 |
2003-07-31 |
Adipogenix, Inc. |
Fat accumulation-modulation compounds
|
US6841566B2
(en)
|
2001-07-20 |
2005-01-11 |
Boehringer Ingelheim, Ltd. |
Viral polymerase inhibitors
|
US7427623B2
(en)
|
2001-09-11 |
2008-09-23 |
Smithkline Beecham Corporation |
4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
|
PA8557501A1
(es)
|
2001-11-12 |
2003-06-30 |
Pfizer Prod Inc |
Benzamida, heteroarilamida y amidas inversas
|
JP2003155285A
(ja)
|
2001-11-19 |
2003-05-27 |
Toray Ind Inc |
環状含窒素誘導体
|
JP2003221386A
(ja)
|
2001-11-26 |
2003-08-05 |
Takeda Chem Ind Ltd |
二環性誘導体、その製造法およびその用途
|
CZ2004747A3
(cs)
|
2001-12-21 |
2004-11-10 |
Novo Nordisk A/S |
Deriváty amidů jako GK aktivátory
|
TW200307539A
(en)
|
2002-02-01 |
2003-12-16 |
Bristol Myers Squibb Co |
Cycloalkyl inhibitors of potassium channel function
|
TW200304820A
(en)
|
2002-03-25 |
2003-10-16 |
Avanir Pharmaceuticals |
Use of benzimidazole analogs in the treatment of cell proliferation
|
TW200403058A
(en)
|
2002-04-19 |
2004-03-01 |
Bristol Myers Squibb Co |
Heterocyclo inhibitors of potassium channel function
|
FR2840807B1
(fr)
|
2002-06-12 |
2005-03-11 |
|
Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
|
US7122580B2
(en)
|
2002-08-09 |
2006-10-17 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds and methods to modulate coagulation
|
GB0221443D0
(en)
|
2002-09-16 |
2002-10-23 |
Glaxo Group Ltd |
Pyridine derivates
|
JP3546208B2
(ja)
*
|
2002-10-02 |
2004-07-21 |
明治製菓株式会社 |
経口吸収性が改善された抗菌性医薬組成物
|
EP1554271A1
(en)
|
2002-10-15 |
2005-07-20 |
Rigel Pharmaceuticals, Inc. |
Substituted indoles and their use as hcv inhibitors
|
US7514431B2
(en)
|
2002-10-30 |
2009-04-07 |
Merck & Co., Inc. |
Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity
|
US7910030B2
(en)
|
2002-11-26 |
2011-03-22 |
Universiteit Gent |
Process and apparatus for continuous wet granulation of powder material
|
JP2006512338A
(ja)
|
2002-12-12 |
2006-04-13 |
ファルマシア・コーポレーション |
マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−2阻害剤としてのアミノシアノピリジンの使用法
|
DK1585739T3
(da)
|
2003-01-06 |
2011-06-20 |
Lilly Co Eli |
Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
|
CA2755297A1
(en)
|
2003-02-10 |
2004-08-26 |
Vertex Pharmaceuticals Incorporated |
Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
|
US7223788B2
(en)
|
2003-02-14 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
|
WO2004080972A1
(en)
|
2003-03-12 |
2004-09-23 |
Vertex Pharmaceuticals Incorporated |
Pirazole modulators of atp-binding cassette transporters
|
CN1812977A
(zh)
|
2003-04-30 |
2006-08-02 |
药物研发有限责任公司 |
取代羧酸
|
DE602004022819D1
(de)
|
2003-06-06 |
2009-10-08 |
Vertex Pharma |
Von atp-bindende kassette transportern
|
GB0315111D0
(en)
|
2003-06-27 |
2003-07-30 |
Cancer Rec Tech Ltd |
Substituted 5-membered ring compounds and their use
|
AU2004253541B2
(en)
|
2003-06-27 |
2010-10-28 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Amphiphilic pyridinium compounds, method of making and use thereof
|
JP2005053902A
(ja)
|
2003-07-18 |
2005-03-03 |
Nippon Nohyaku Co Ltd |
フェニルピリジン類、その中間体及びこれを有効成分とする除草剤
|
CA2537829A1
(en)
|
2003-09-05 |
2005-03-17 |
Neurogen Corporation |
Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
|
RU2006111093A
(ru)
|
2003-09-06 |
2007-10-27 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Модуляторы атр-связывающих кассетных транспортеров
|
US7534894B2
(en)
|
2003-09-25 |
2009-05-19 |
Wyeth |
Biphenyloxy-acids
|
US20050070718A1
(en)
|
2003-09-30 |
2005-03-31 |
Abbott Gmbh & Co. Kg |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
AU2004279855A1
(en)
|
2003-10-08 |
2005-04-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups
|
JPWO2005037269A1
(ja)
|
2003-10-21 |
2006-12-28 |
住友製薬株式会社 |
新規ピペリジン誘導体
|
FR2861304B1
(fr)
|
2003-10-23 |
2008-07-18 |
Univ Grenoble 1 |
Modulateurs des canaux cftr
|
GB0325956D0
(en)
|
2003-11-06 |
2003-12-10 |
Addex Pharmaceuticals Sa |
Novel compounds
|
ZA200604578B
(en)
|
2003-11-14 |
2008-05-28 |
Vertex Pharma |
Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters
|
EP1687001A2
(en)
|
2003-11-19 |
2006-08-09 |
Glaxo Group Limited |
Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
|
ES2238001B1
(es)
|
2004-01-21 |
2006-11-01 |
Vita Cientifica, S.L. |
Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
EP3219709B1
(en)
|
2004-01-30 |
2020-03-18 |
Vertex Pharmaceuticals Incorporated |
Intermediate compound of modulators of atp-binding cassette transporters
|
CN100567270C
(zh)
|
2004-02-19 |
2009-12-09 |
万有制药株式会社 |
磺酰胺衍生物
|
CZ23088U1
(cs)
*
|
2004-03-25 |
2011-12-19 |
Astellas Pharma Inc. |
Kompozice pevného farmaceutického prípravku solifenacinu nebo jeho soli
|
ES2241496B1
(es)
|
2004-04-15 |
2006-12-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de piridina.
|
WO2005115399A2
(en)
|
2004-04-16 |
2005-12-08 |
Neurogen Corporation |
Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands
|
US7585885B2
(en)
|
2004-04-22 |
2009-09-08 |
Eli Lilly And Company |
Pyrrolidine derivatives useful as BACE inhibitors
|
JP2007533740A
(ja)
|
2004-04-22 |
2007-11-22 |
イーライ リリー アンド カンパニー |
Bace阻害剤としてのアミド
|
EP1766062A4
(en)
|
2004-06-01 |
2008-07-09 |
Tm Bioscience Corp |
METHOD FOR DETECTING MUTATIONS ASSOCIATED WITH CYSTIC FIBROSIS
|
TWI356036B
(en)
|
2004-06-09 |
2012-01-11 |
Smithkline Beecham Corp |
Apparatus and method for pharmaceutical production
|
US20140343098A1
(en)
|
2004-06-24 |
2014-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
ME02156B
(me)
|
2004-06-24 |
2015-10-20 |
Vertex Pharma |
Modulatori atp-vezujućih kasetnih transportera
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
MX2007000308A
(es)
|
2004-07-01 |
2007-04-10 |
Warner Lambert Co |
Preparacion de composiciones farmaceuticas que contienen nanoparticulas.
|
US8715727B2
(en)
|
2004-07-02 |
2014-05-06 |
Shionogi Inc. |
Tablet for pulsed delivery
|
CN1993339B
(zh)
|
2004-08-06 |
2013-05-22 |
大塚制药株式会社 |
芳香化合物
|
US20060069110A1
(en)
|
2004-09-27 |
2006-03-30 |
Andersen Denise L |
Substituted heterocyclic compounds and methods of use
|
WO2006040520A1
(en)
|
2004-10-12 |
2006-04-20 |
Astrazeneca Ab |
Quinazoline derivatives
|
CA2587461A1
(en)
|
2004-11-15 |
2006-05-18 |
Pfizer Products Inc. |
Azabenzoxazoles for the treatment of cns disorders
|
ME01868B
(me)
|
2004-12-15 |
2010-10-31 |
Dompe Pha R Ma Spa Res & Mfg |
Derivati 2-arilpropionske kiseline i farmaceutske smeše, koje ih sadrže
|
JP4790260B2
(ja)
|
2004-12-22 |
2011-10-12 |
出光興産株式会社 |
アントラセン誘導体を用いた有機エレクトロルミネッセンス素子
|
US20080146612A1
(en)
|
2005-01-27 |
2008-06-19 |
Astrazeneca Ab |
Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
|
US7888374B2
(en)
|
2005-01-28 |
2011-02-15 |
Abbott Laboratories |
Inhibitors of c-jun N-terminal kinases
|
US20090048258A1
(en)
|
2005-02-01 |
2009-02-19 |
Masaki Ogino |
Amide Compound
|
US8242149B2
(en)
|
2005-03-11 |
2012-08-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US7297700B2
(en)
|
2005-03-24 |
2007-11-20 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
TWI377206B
(en)
|
2005-04-06 |
2012-11-21 |
Theravance Inc |
Crystalline form of a quinolinone-carboxamide compound
|
EP1710246A1
(en)
|
2005-04-08 |
2006-10-11 |
Schering Aktiengesellschaft |
Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
|
TW200716594A
(en)
|
2005-04-18 |
2007-05-01 |
Neurogen Corp |
Substituted heteroaryl CB1 antagonists
|
BRPI0610850A2
(pt)
|
2005-04-19 |
2008-12-02 |
Bayer Pharmaceuticals Corp |
derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
|
CN101160126A
(zh)
|
2005-04-20 |
2008-04-09 |
默克公司 |
血管紧张肽ⅱ受体拮抗剂
|
BRPI0610785A2
(pt)
|
2005-04-22 |
2016-09-13 |
Wyeth Corp |
polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição
|
GB0510139D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds B1
|
CN101223146A
(zh)
|
2005-05-24 |
2008-07-16 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
JP2008545744A
(ja)
|
2005-06-02 |
2008-12-18 |
バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト |
フェニルアルキル置換ヘテロアリール誘導体
|
EP1919875A2
(en)
|
2005-06-21 |
2008-05-14 |
Astex Therapeutics Limited |
Pyrazole derivatives and their use as pka and pkb modulators
|
CA2618057A1
(en)
|
2005-08-11 |
2007-02-22 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
ES2367844T3
(es)
|
2005-08-11 |
2011-11-10 |
Vertex Pharmaceuticals, Inc. |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística.
|
MY145713A
(en)
|
2005-09-09 |
2012-03-30 |
Smithkline Beecham Corp |
Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders
|
MY143784A
(en)
|
2005-09-23 |
2011-07-15 |
Hoffmann La Roche |
Novel dosage formulation
|
CA2624683A1
(en)
|
2005-10-06 |
2007-04-19 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
BRPI0618417A2
(pt)
|
2005-10-19 |
2012-07-31 |
Gruenenthal Chemie |
novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos
|
US20120232059A1
(en)
|
2005-11-08 |
2012-09-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette Transporters
|
WO2007054480A1
(en)
|
2005-11-08 |
2007-05-18 |
N.V. Organon |
2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
|
ES2431388T3
(es)
|
2005-11-08 |
2013-11-26 |
Vertex Pharmaceuticals Incorporated |
Compuesto heterocíclico útil como un modulador de transportadores de casete de unión a ATP
|
GB0606891D0
(en)
*
|
2006-04-05 |
2006-05-17 |
Council Cent Lab Res Councils |
Raman Analysis Of Pharmaceutical Tablets
|
CN101326182B
(zh)
|
2005-12-05 |
2011-09-28 |
史密丝克莱恩比彻姆公司 |
2-嘧啶基吡唑并吡啶ErbB激酶抑制剂
|
CA2634113A1
(en)
|
2005-12-24 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Quinolin- 4 - one derivatives as modulators of abc transporters
|
CA2635214A1
(en)
|
2005-12-27 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in cftr assays and methods therewith
|
NZ569327A
(en)
|
2005-12-28 |
2011-09-30 |
Vertex Pharma |
1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
PT1993360T
(pt)
|
2005-12-28 |
2017-05-25 |
Vertex Pharma |
Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
|
EP1966585A2
(en)
|
2005-12-30 |
2008-09-10 |
Caliper Life Sciences, Inc. |
Integrated dissolution processing and sample transfer system
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
CN101460489A
(zh)
|
2006-04-07 |
2009-06-17 |
弗特克斯药品有限公司 |
Atp-结合盒转运蛋白调节剂
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
AU2007249269A1
(en)
|
2006-05-12 |
2007-11-22 |
Vertex Pharmaceuticals Incorporated |
Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
WO2007131930A1
(en)
*
|
2006-05-13 |
2007-11-22 |
Novo Nordisk A/S |
Tablet formulation comprising repaglinide and metformin
|
AU2007351454B2
(en)
|
2006-11-03 |
2013-07-18 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
KR20090083408A
(ko)
|
2006-11-27 |
2009-08-03 |
노파르티스 아게 |
치환된 디히드로이미다졸 및 종양 치료에서의 그의 용도
|
JP2008183168A
(ja)
*
|
2007-01-30 |
2008-08-14 |
Ebara Corp |
錠剤製造システム
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
NZ599556A
(en)
|
2007-05-02 |
2013-10-25 |
Portola Pharm Inc |
Combination therapy with a compound acting as a platelet adp receptor inhibitor
|
AU2008251504B2
(en)
|
2007-05-09 |
2013-07-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
HUE025553T2
(en)
|
2007-05-25 |
2016-02-29 |
Vertex Pharma |
CFTR modulators
|
US20110177999A1
(en)
|
2007-08-09 |
2011-07-21 |
Vertex Pharmaceuticals Incorporated |
Therapeutic Combinations Useful in Treating CFTR Related Diseases
|
NZ583420A
(en)
|
2007-08-24 |
2012-06-29 |
Vertex Pharma |
Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
|
DE102007042754A1
(de)
|
2007-09-07 |
2009-03-12 |
Bayer Healthcare Ag |
Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
|
CN101821266B
(zh)
|
2007-09-14 |
2014-03-12 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜通道调节因子的调节剂
|
AU2008301907B2
(en)
|
2007-09-14 |
2014-02-20 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
FR2921657A1
(fr)
|
2007-09-28 |
2009-04-03 |
Sanofi Aventis Sa |
Derives de nicotinamide, leur preparation et leur application en therapeutique
|
NZ585980A
(en)
|
2007-11-16 |
2012-04-27 |
Vertex Pharma |
Isoquinoline modulators of atp-binding cassette transporters
|
SG186638A1
(en)
|
2007-12-07 |
2013-01-30 |
Vertex Pharma |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
JP2011506331A
(ja)
|
2007-12-07 |
2011-03-03 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の処方物
|
RS56083B1
(sr)
|
2007-12-07 |
2017-10-31 |
Vertex Pharma |
Proces za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina
|
EP2231671B1
(en)
|
2007-12-13 |
2013-04-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
JP2011511011A
(ja)
*
|
2008-02-05 |
2011-04-07 |
ハーバー バイオサイエンシーズ,インコーポレイテッド |
医薬的固体状態形態
|
WO2009108657A2
(en)
|
2008-02-28 |
2009-09-03 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl derivatives as cftr modulators
|
PT2615085E
(pt)
|
2008-03-31 |
2015-10-09 |
Vertex Pharma |
Derivados piridilo como moduladores cftr
|
GB0813709D0
(en)
|
2008-07-26 |
2008-09-03 |
Univ Dundee |
Method and product
|
KR20110042356A
(ko)
|
2008-08-13 |
2011-04-26 |
버텍스 파마슈티칼스 인코포레이티드 |
제약 조성물 및 그의 투여
|
US20100256184A1
(en)
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
AR073709A1
(es)
|
2008-09-29 |
2010-11-24 |
Vertex Pharma |
Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
|
JP5645834B2
(ja)
|
2008-10-23 |
2014-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
嚢胞性線維症膜コンダクタンス制御因子の修飾因子
|
KR20110074917A
(ko)
|
2008-10-23 |
2011-07-04 |
버텍스 파마슈티칼스 인코포레이티드 |
낭포성 섬유증 막횡단 전도도 조정자의 조절인자
|
JP5645835B2
(ja)
|
2008-10-23 |
2014-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
N−(4−(7−アザビシクロ[2.2.1]ヘプタン−7−イル)−2−(トリフルオロメチル)フェニル)−4−オキソ−5−(トリフルオロメチル)−1,4−ジヒドロキノリン−3−カルボキサミドの固体形態
|
US20110257223A1
(en)
|
2008-10-23 |
2011-10-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
|
ME02105B
(me)
|
2008-11-06 |
2015-10-20 |
Vertex Pharma |
Modulatori atp-vezujucih kasetnih transportera
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
US8367660B2
(en)
|
2008-12-30 |
2013-02-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
DK2408749T3
(en)
|
2009-03-20 |
2018-08-13 |
Vertex Pharma |
CYSTIC FIBROSE TRANSMEMBRAN CONDUCTOR CONTROLLER MODULATORS
|
CA3071058C
(en)
|
2009-03-20 |
2023-01-24 |
Vertex Pharmaceuticals Incorporated |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
US8481678B2
(en)
*
|
2009-03-30 |
2013-07-09 |
E I Du Pont De Nemours And Company |
Peptide-based tooth whitening reagents
|
EP2427166B1
(en)
|
2009-05-07 |
2013-10-16 |
Gea Pharma Systems Limited |
Tablet production module and method for continuous production of tablets
|
JP5355269B2
(ja)
*
|
2009-07-16 |
2013-11-27 |
大日本住友製薬株式会社 |
顕微ラマン分光法による固体材料中の分散粒子の粒径の測定法
|
NZ598277A
(en)
|
2009-09-17 |
2014-03-28 |
Vertex Pharma |
Process for preparing azabicyclic compounds
|
CN102665715A
(zh)
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
AU2010310617A1
(en)
|
2009-10-23 |
2012-05-24 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
|
JP5789611B2
(ja)
|
2009-10-23 |
2015-10-07 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを調製するためのプロセス
|
EP2547658A1
(en)
|
2010-03-19 |
2013-01-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
DK2826776T3
(da)
|
2010-03-25 |
2020-12-14 |
Vertex Pharma |
Fast dispersion af amorf form af (r)-1(2,2-difluorbenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluor-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropancarboxamid
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
NZ602838A
(en)
|
2010-04-07 |
2015-06-26 |
Vertex Pharma |
Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
|
PL2555754T3
(pl)
|
2010-04-07 |
2016-09-30 |
|
Formy stałe kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
|
WO2011133953A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
CA2796646A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
JP2013525371A
(ja)
|
2010-04-22 |
2013-06-20 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
シクロアルキルカルボキサミド−インドール化合物の製造方法
|
EP3138563A1
(en)
|
2010-04-22 |
2017-03-08 |
Vertex Pharmaceuticals Inc. |
Pharmaceutical compositions and administrations thereof
|
US8404849B2
(en)
|
2010-05-20 |
2013-03-26 |
Vertex Pharmaceuticals |
Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
|
CA2798412A1
(en)
|
2010-05-20 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
RU2013112937A
(ru)
|
2010-08-23 |
2014-09-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтические композиции (r)-1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)-n-(2, 3-дигидроксипропил)-6-фтор-2-(1-гидрокси-2-метилпропан-2-ил)-1н-индол-5-ил)циклопропанкарбоксамида и их применение
|
CN103153286A
(zh)
|
2010-08-27 |
2013-06-12 |
沃泰克斯药物股份有限公司 |
药物组合物及其施用
|
CN102058889A
(zh)
|
2010-11-05 |
2011-05-18 |
王定豪 |
包含抗凝血类药物的分散片及其应用
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
US10092660B2
(en)
|
2011-04-25 |
2018-10-09 |
Stc.Unm |
Solid compositions for pharmaceutical use
|
JP5798400B2
(ja)
*
|
2011-07-26 |
2015-10-21 |
富士電機株式会社 |
医薬品製造制御装置、医薬品製造制御方法、医薬品製造制御プログラム、医薬品製造システム
|
EP2773349A1
(en)
|
2011-11-02 |
2014-09-10 |
Vertex Pharmaceuticals Incorporated |
Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
|
US20140127901A1
(en)
|
2012-11-08 |
2014-05-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Low-k damage free integration scheme for copper interconnects
|
US9254291B2
(en)
|
2011-11-08 |
2016-02-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
JP2015504920A
(ja)
|
2012-01-25 |
2015-02-16 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の製剤
|
AU2013226076B2
(en)
|
2012-02-27 |
2017-11-16 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administration thereof
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
EP2659890A1
(en)
*
|
2012-04-30 |
2013-11-06 |
Orphan Synergy Europe - Pharma |
Methods and compositions for the treatment of fibrosis
|
AU2013270681A1
(en)
|
2012-06-08 |
2014-12-18 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of CFTR -mediated disorders
|
AU2013290444B2
(en)
|
2012-07-16 |
2018-04-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
US20140092376A1
(en)
|
2012-10-01 |
2014-04-03 |
Momentive Performance Materials, Inc. |
Container and method for in-line analysis of protein compositions
|
SG10201703452PA
(en)
|
2012-11-02 |
2017-06-29 |
Vertex Pharma |
Pharmaceutical compositions for the treatment of cftr mediated diseases
|
US20140221424A1
(en)
|
2013-01-30 |
2014-08-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for use in the treatment of cystic fibrosis
|
EP4223294A1
(en)
|
2014-04-15 |
2023-08-09 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
|
LT3203840T
(lt)
|
2014-10-06 |
2020-10-26 |
Vertex Pharmaceuticals Incorporated |
Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai
|
EP3204358B1
(en)
|
2014-10-07 |
2018-09-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
WO2016086136A1
(en)
|
2014-11-26 |
2016-06-02 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
|
MA41031A
(fr)
|
2014-11-26 |
2017-10-03 |
Catabasis Pharmaceuticals Inc |
Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
|
EP3226861A2
(en)
|
2014-12-05 |
2017-10-11 |
Centre National de la Recherche Scientifique (CNRS) |
Compounds for treating cystic fibrosis
|
WO2016123028A1
(en)
|
2015-01-26 |
2016-08-04 |
Rigel Pharmaceuticals, Inc. |
Tetrazolones as carboxylic acid bioisosteres
|
UY36680A
(es)
|
2015-05-19 |
2016-12-30 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas como inhibidores de quinasa
|